Drug Profile

Parsaclisib - Incyte Corporation

Alternative Names: IBI-376; INCB-050465; INCB-50465

Latest Information Update: 20 Feb 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Incyte Corporation
Developer Incyte Corporation; Innovent Biologics; Mayo Clinic; National Cancer Institute (USA)
Class Antianaemics; Antihaemorrhagics; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Ketones; Pyrazoles; Pyrimidines; Pyrrolidines; Small molecules
Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Marginal zone B-cell lymphoma; Mantle-cell lymphoma; Autoimmune haemolytic anaemia; Follicular lymphoma
New Molecular Entity Yes

Preregistration Follicular lymphoma
Phase III Myelofibrosis
Phase II B-cell lymphoma; Diffuse large B cell lymphoma; Mantle-cell lymphoma; Marginal zone B-cell lymphoma
Phase I/II Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Solid tumours
No development reported Systemic lupus erythematosus
Discontinued Autoimmune haemolytic anaemia; Sjogren's syndrome

07 Dec 2024 Efficacy and adverse events data from a phase I/Ib trial in Diffuse large B-cell lymphoma presented at the 66^th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
22 Oct 2024 Incyte Corporation completes the phase-I/II topMIND trial in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in in the US, Austria, Belgium, France, Germany, Italy and Spain (PO, Tablet) (NCT04809467) (EudraCT2020-005591-35)
28 Jul 2024 No recent reports of development identified for phase-I development in B-cell lymphoma(Second-line therapy or greater) in Japan (PO, Tablet)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com